Company Registration No. 08925012 (England and Wales)
Angulus Pharma Limited
Unaudited accounts
for the year ended 31 May 2024
Angulus Pharma Limited
Unaudited accounts
Contents
Angulus Pharma Limited
Company Information
for the year ended 31 May 2024
Company Number
08925012 (England and Wales)
Registered Office
128 City Road
London
EC1V 2NX
Accountants
Wellington Consulting Ltd
Fairview
St Owens Cross
Hereford
Herefordshire
HR2 8LG
Angulus Pharma Limited
Accountants' report
Accountants' report to the director of Angulus Pharma Limited on the preparation of the unaudited statutory accounts for the year ended 31 May 2024
In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of
Angulus Pharma Limited for the year ended
31 May 2024 as set out on pages
5 -
7 from the company's accounting records and from information and explanations you have given us.
This report is made solely to the Board of Directors of Angulus Pharma Limited, as a body, in accordance with the terms of our engagement. Our work has been undertaken solely to prepare for your approval the accounts of Angulus Pharma Limited and state those matters that we have agreed to state to them, as a body, in this report. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Angulus Pharma Limited and its Board of Directors as a body for our work or for this report.
It is your duty to ensure that Angulus Pharma Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Angulus Pharma Limited. You consider that Angulus Pharma Limited is exempt from the statutory audit requirement for the year.
We have not been instructed to carry out an audit or a review of the accounts of Angulus Pharma Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.
Wellington Consulting Ltd
Fairview
St Owens Cross
Hereford
Herefordshire
HR2 8LG
25 February 2025
Angulus Pharma Limited
Statement of financial position
as at 31 May 2024
Cash at bank and in hand
177
37
Creditors: amounts falling due within one year
(6,866)
(6,366)
Net current liabilities
(2,831)
(6,292)
Total assets less current liabilities
(2,581)
(5,791)
Creditors: amounts falling due after more than one year
(84,892)
(84,312)
Net liabilities
(87,473)
(90,103)
Called up share capital
100
100
Capital contribution reserve
260,935
260,935
Profit and loss account
(348,508)
(351,138)
Shareholders' funds
(87,473)
(90,103)
For the year ending 31 May 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 25 February 2025 and were signed on its behalf by
Dr Albert Chan
Director
Company Registration No. 08925012
Angulus Pharma Limited
Notes to the Accounts
for the year ended 31 May 2024
Angulus Pharma Limited is a private company, limited by shares, registered in England and Wales, registration number 08925012. The registered office is 128 City Road, London, EC1V 2NX.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts have been prepared on a going concern basis as the director has confirmed that he will continue to provide financial support to the company to enable it to meet its financial liabilities for the foreseeable future.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives with an adjustment to correct an earlier year error:
Computer equipment
25% straight line basis
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
The main creditor is the sole director and shareholder who does not intend seeking repayment until the company can afford to repay him.
Angulus Pharma Limited
Notes to the Accounts
for the year ended 31 May 2024
4
Tangible fixed assets
Computer equipment
Amounts falling due within one year
6
Creditors: amounts falling due within one year
2024
2023
Trade creditors
4,617
4,822
Other creditors
2,149
1,424
The trade creditors include two invoices under query to the value of £4,617.
7
Creditors: amounts falling due after more than one year
2024
2023
Loans from directors
84,892
84,312
The balance of £84,892 (2023 - £84,312) is due to the sole shareholder who does not seek repayment until the company is in a position to repay the loan.
8
Average number of employees
During the year the average number of employees was 1 (2023: 1).